For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240304:nRSD3674Fa&default-theme=true
RNS Number : 3674F Alliance Pharma PLC 04 March 2024
For immediate release 4 March 2024
ALLIANCE PHARMA PLC
("Alliance", "Company" or "Group")
Notification of Full Year Results, Analyst Meeting and Webcast
Alliance Pharma plc (AIM: APH), the international healthcare group, will
announce its results for the year ended 31 December 2023 on Tuesday 9 April
2024.
A meeting for analysts will be held at 9.30am on the day of the results at
Buchanan, 107 Cheapside, London EC2V 6DN. To register for the meeting,
analysts are invited to contact Buchanan at alliancepharma@buchanan.uk.com
(mailto:alliancepharma@buchanan.uk.com)
A live webcast of the analyst meeting will be accessible via the following
link:
https://stream.buchanan.uk.com/broadcast/65e0c6b14fdf0119e94f5747
(https://stream.buchanan.uk.com/broadcast/65e0c6b14fdf0119e94f5747)
A recording of the webcast will be made available following the meeting at the
investor section of Alliance's website,
https://www.alliancepharmaceuticals.com/investors
(https://www.alliancepharmaceuticals.com/investors)
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications + 44 (0)1249 705168
ir@allianceph.com (mailto:ir@allianceph.com)
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills
alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)
Deutsche Numis (Nominated Adviser and Joint Broker) + 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Sher Shah
Investec Bank plc (Joint Broker) + 44 (0)20 7597 5970
Patrick Robb / Maria Gomez de Olea
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our
purpose is to empower people to make a positive difference to their health and
wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and
channels, in related innovation, and through selective geographic expansion to
increase the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics we remain asset-light and focused
on maximising the value we can bring, both to our stakeholders and to our
brands.
For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NORQKNBBKBKBBNK